NuCana plc NASDAQ:NCNA

Founder-led company

NuCana stock price today

$3.7
+2.28
+160.56%
Financial Health
0
1
2
3
4
5
6
7
8
9

NuCana stock price monthly change

-54.92%
month

NuCana stock price quarterly change

-54.92%
quarter

NuCana stock price yearly change

+373.33%
year

NuCana key metrics

Market Cap
4.94M
Enterprise value
N/A
P/E
-1.41
EV/Sales
N/A
EV/EBITDA
0.04
Price/Sales
N/A
Price/Book
0.67
PEG ratio
-0.38
EPS
-12.58
Revenue
N/A
EBITDA
-29.59M
Income
-26.60M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

NuCana stock price history

NuCana stock forecast

NuCana financial statements

NuCana plc (NASDAQ:NCNA): Profit margin
Jun 2023 0 -5.41M
Sep 2023 0 -6.69M
Dec 2023 0 -7.65M
Mar 2024 0 -6.83M
NuCana plc (NASDAQ:NCNA): Analyst Estimates
Sep 2025 0 -63.19K
Dec 2025 0 -53.60K
Dec 2025 0 -62.55K
Mar 2026 0 -61.98K
  • Analysts Price target

  • Financials & Ratios estimates

NuCana plc (NASDAQ:NCNA): Debt to assets
Jun 2023 41257000 13.87M 33.63%
Sep 2023 33967000 12.19M 35.9%
Dec 2023 27811000 12.92M 46.47%
Mar 2024 24801000 14.67M 59.16%
NuCana plc (NASDAQ:NCNA): Cash Flow
Jun 2023 -5.85M 23K -33K
Sep 2023 -10.17M 2.64M 64K
Dec 2023 -77K 53K -43K
Mar 2024 -5.88M 43K 1.38M

NuCana alternative data

NuCana plc (NASDAQ:NCNA): Employee count
Aug 2023 28
Sep 2023 28
Oct 2023 28
Nov 2023 28
Dec 2023 28
Jan 2024 28
Feb 2024 28
Mar 2024 28
Apr 2024 28
May 2024 25
Jun 2024 25
Jul 2024 25

NuCana other data

33.56% -7.05%
of NCNA is owned by hedge funds
17.46M -3.71M
shares is hold by hedge funds
Patent
Grant
Filling date: 18 Sep 2018 Issue date: 16 Aug 2022
Grant
Filling date: 14 Jun 2018 Issue date: 16 Aug 2022
Grant
Filling date: 31 May 2017 Issue date: 2 Aug 2022
Grant
Filling date: 21 Dec 2016 Issue date: 5 Jul 2022
Grant
Filling date: 5 Feb 2020 Issue date: 7 Jun 2022
Application
Filling date: 19 May 2021 Issue date: 3 Feb 2022
Application
Filling date: 18 May 2021 Issue date: 3 Feb 2022
Application
Filling date: 15 Apr 2021 Issue date: 3 Feb 2022
Application
Filling date: 1 Oct 2021 Issue date: 27 Jan 2022
Application
Filling date: 6 Apr 2021 Issue date: 27 Jan 2022
Insider Compensation
Mr. Hugh Stephen Griffith (1968) Founder, Chief Executive Officer & Executive Director
$1,240,000
Prof. Christopher B. Wood FRCS, M.D., Ph.D. (1946) Chief Medical Officer
$111,880
Monday, 25 November 2024
globenewswire.com
Monday, 11 November 2024
globenewswire.com
Friday, 4 October 2024
gurufocus.com
Wednesday, 25 September 2024
globenewswire.com
Tuesday, 17 September 2024
zacks.com
Saturday, 14 September 2024
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Thursday, 15 August 2024
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
Tuesday, 21 May 2024
globenewswire.com
Thursday, 16 May 2024
globenewswire.com
Wednesday, 1 May 2024
globenewswire.com
Tuesday, 9 April 2024
globenewswire.com
Wednesday, 27 March 2024
globenewswire.com
Wednesday, 20 March 2024
globenewswire.com
Wednesday, 13 March 2024
InvestorPlace
Wednesday, 3 January 2024
Seeking Alpha
Wednesday, 8 November 2023
GlobeNewsWire
Tuesday, 10 October 2023
InvestorPlace
Thursday, 28 September 2023
Zacks Investment Research
Thursday, 1 June 2023
GlobeNewsWire
Monday, 27 March 2023
InvestorPlace
Tuesday, 28 February 2023
GlobeNewsWire
Sunday, 8 January 2023
Seeking Alpha
Monday, 21 November 2022
Zacks Investment Research
Wednesday, 5 October 2022
Zacks Investment Research
Wednesday, 28 September 2022
Zacks Investment Research
Zacks Investment Research
Thursday, 22 September 2022
Seeking Alpha
Wednesday, 13 July 2022
Seeking Alpha
  • What's the price of NuCana stock today?

    One share of NuCana stock can currently be purchased for approximately $3.7.

  • When is NuCana's next earnings date?

    Unfortunately, NuCana's (NCNA) next earnings date is currently unknown.

  • Does NuCana pay dividends?

    No, NuCana does not pay dividends.

  • How much money does NuCana make?

    NuCana has a market capitalization of 4.94M.

  • What is NuCana's stock symbol?

    NuCana plc is traded on the NASDAQ under the ticker symbol "NCNA".

  • What is NuCana's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of NuCana?

    Shares of NuCana can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are NuCana's key executives?

    NuCana's management team includes the following people:

    • Mr. Hugh Stephen Griffith Founder, Chief Executive Officer & Executive Director(age: 57, pay: $1,240,000)
    • Prof. Christopher B. Wood FRCS, M.D., Ph.D. Chief Medical Officer(age: 79, pay: $111,880)
  • Is NuCana founder-led company?

    Yes, NuCana is a company led by its founder Mr. Hugh Stephen Griffith.

  • How many employees does NuCana have?

    As Jul 2024, NuCana employs 25 workers, which is 11% less then previous quarter.

  • When NuCana went public?

    NuCana plc is publicly traded company for more then 7 years since IPO on 28 Sep 2017.

  • What is NuCana's official website?

    The official website for NuCana is nucana.com.

  • How can i contact NuCana?

    NuCana can be reached via phone at +44 131 357 1111.

NuCana company profile:

NuCana plc

nucana.com
Exchange:

NASDAQ

Full time employees:

25

Industry:

Biotechnology

Sector:

Healthcare

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

3 Lochside Way
Edinburgh, EH12 9DT

CIK: 0001709626
ISIN: US67022C1062
CUSIP: 67022C106